Physician profile
Corey Holt
NPI 1306461090
$1,332.59
in general payments reported to CMS, 2019-2025
12 companies · $707 in 2025
The $707 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $47.71 · 2024: $578 · 2025: $707.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,333.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,332.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $390.71 | 2024-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $345.53 | 2023-2025 | |
| Pfizer INC. | $199.11 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $83.99 | 2023-2025 | Farxiga |
| Lilly USA, LLC | $75.77 | 2024-2025 | Zepbound, Jardiance, Mounjaro |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $55.67 | 2024-2025 | Caplyta |
| Astellas Pharma US INC | $46.08 | 2024-2025 | Veozah |
| Merck Sharp & Dohme LLC | $37.01 | 2024-2025 | Vaxneuvance, Gardasil 9, Capvaxive |
| Glaxosmithkline, LLC. | $34.29 | 2025 | Trelegy Ellipta |
| Amgen INC. | $27.04 | 2025 | Repatha, Otezla |
| Tanabe Pharma America, INC. | $21.43 | 2025 | Radicava |
| Exact Sciences Corporation | $15.96 | 2024 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corey Holt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.